期刊文献+

过氧化物酶体增殖物激活受体-γ在人侵袭性垂体腺瘤中的分布与表达 被引量:2

Distribution and expression of peroxisome proliferator activated receptor-γ in human invasive pituitary adenomas
下载PDF
导出
摘要 目的研究过氧化物酶体增殖物激活受体-γ(PPAR-γ)在人侵袭性垂体腺瘤组织中的分布情况和表达水平。方法30例垂体腺瘤组织依据影像学Knosp分级及术中所见分为侵袭组与非侵袭组。免疫组织化学染色分析PPAR-γ在垂体腺瘤组织中的分布情况,W estern B lot分析PPAR-γ在垂体腺瘤中的表达水平,比较PPAR-γ在侵袭性组与非侵袭组之间、各种内分泌类型腺瘤的侵袭组与非侵袭组之间分布与表达差异。结果侵袭组PPAR-γ表达水平明显高于非侵袭性组(P<0.05),侵袭性泌乳素腺瘤、侵袭性无功能腺瘤中PPAR-γ的表达水平显著高于相应的非侵袭组(P<0.05),而在生长激素腺瘤中,侵袭组与非侵袭组间PPAR-γ表达水平无明显差异(P>0.1)。结论PPAR-γ可能在人垂体腺瘤侵袭性方面发挥重要作用,并有可能成为侵袭性垂体腺瘤治疗的新靶点。 Objective To evaluate the distribution and expression of peroxisome proliferator activated receptor-γ (PPAR-γ) in human invasive pituitary adenomas. Methods Thirty consecutive surgically resected pituitary adenomas were divided into invasive group and non-invasive group according to the Knosp grade or exhibitions in operations. Immunohistochemistry was used to confirm the distribution of PPAR-γand the staining positive rates were compared between the two groups. The expression of PPAR-γ was evaluated by Western Blot. Results PPAR-γ immunoreactivity was located in nucleoli of pituitary adenoma cells. The staining positive rate in invasive group was markedly higher than that in non-invasive group ( P 〈 0. 05). The expression in invasive group was significantly higher than that in non-invasive group ( P 〈 0. 05). In non-functional and prolactin- secreting pituitary adenomas, the expression of PPAR-γ in the invasive group was more abundant than that in the non-invasive group. There was no significant difference of PPAR-γ expression between growth hormone -secreting invasive and non-invasive adenomas (P 〉0. 1 ). Conclusion PPAR-γ may play an important role in the invasion of human pituitary adenomas and may be a novel therapeutic target of invasive pituitary adenomas.
出处 《中华神经外科疾病研究杂志》 CAS 2006年第3期203-205,共3页 Chinese Journal of Neurosurgical Disease Research
关键词 过氧化物酶体增殖物激活受体-Γ 垂体腺瘤 侵袭性 Peroxisome proliferator activated receptor-γ Pituitary adenoma Invasion
  • 相关文献

参考文献6

  • 1Knosp E,Steiner E,Kitz K,et al.Pituitary adenomas with invasive of the cavernous sinus space:a magnetic resonance imaging classification compared with surgical findings[J].Neurosurgery,1993,33(4):610-618.
  • 2Schimizu M,Saitoh Y,Itoh H.Immunohistochemical staining of Ha-ras oncogene product in normal,benign,and malignant human pancreatic tissues[J].Hum Pathol,1990,21(6):607-612.
  • 3Heaney AP,Fernando M,Melmed S.PPAR-γ receptor ligands:novel therapy for pituitary adenomas[J].J Clin Invest,2003,111(9):1381-1388.
  • 4Bogazzi F,Ultimieri F,Raggi F,et al.Peroxisome proliferator activated recptor-γ expression is reduced in the colonic mucosa of acromegalic patients[J].J Clin Endocrinol Metab,2002,87(5):2403-2406.
  • 5Khalfallah Y,Sassolas G,Borson-Chazot F,et al.Expression of insulin target genes in skeletal muscle and adipose tissue in adult patients with growth hormone deficiency:effect of one year recombinant human growth hormone therapy[J].J Endocrinol,2001,171(2):285-292.
  • 6Ransohoff RM.Cellular responses to interferons and other cytokines:the JAK-ATAT paradigm[J].N Engl J Med,1998,338(9):616-618.

同被引文献27

  • 1任祖渊.垂体腺瘤[M]//32忠诚.王忠诚神经外科学.武汉:湖北科学技术出版社,2005:620.
  • 2I-Ian S, Roman J. Peroxisome proliferators-activated receptor gamma: a novel target for cancer therapeutics? [ J ]. Anticancer Drugs, 2007,18(3) :237-244.
  • 3Grommes C, Landreth G E, Heneka M T. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists [J]. Lancet Oncol, 2004,5(7) :419-429.
  • 4Lyon C M, Klinge D M, Do K C, et al. Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model [J]. Carcinogenesis, 2009,30(12) : 2095-2099.
  • 5Krieger-Hinck N, Schumacher U, Mtiller A, et al. The effect of the PPAR-gamma agonist Rosiglitazone on neuroblastoma SK-N-SH cells in a metastatic xenograft mouse model [J]. Oncol Res, 2010,18(8) :387-393.
  • 6Aljada A, O'Connor L, Fu Y Y, et al. PPAR gamma ligands, Rosiglitazone and piog|itazone, inhibit bFGF- and VEGF- mediated angiogenesis [J]. Angiogenesis, 2008,11 (4) : 361 - 367.
  • 7Platta CS, Mackay C,Welsh JS. Pituitary adenoma:a radio therapeutic perspective. Am J Clin Oncol,2010,33(4) :408-419.
  • 8Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptoryagonists. Lancet Oncol, 2004,5(7) :419-429.
  • 9Terrasi M,Bazan V ,Caruso S,et al. Effects of PPARγ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells. J Cell Physiol,2012,228 (6) : 1368-1374.
  • 10Sikka S, Chen L, Sethi G, et al. Targeting PPARγ signaling cascade for the prevention and treatment of prostate cancer. PPAR Res, 2012,2012:968040.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部